Publication:
Free Text: A case of cicatricial alopecia associated with erlotinib.


abstract

erlotinib is a small-molecule tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR). Erlotinib has been used primarily to treat non-small cell lung cancer. In addition to its role in tumor cells, EGFR is also an important regulator of growth and differentiation in the skin and hair. Therefore, EGFR-TKIs have been associated with a number of cutaneous side effects including follicular acneiform eruptions, cutaneous xerosis, chronic paronychia, desquamation, seborrheic dermatitis, and hair texture changes. Herein, we report a rare case of a 61-year-old woman who was treated with erlotinib and experienced cicatricial alopecia.

Related Articles
A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
J Cutan Pathol. 2009
A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
Pongpudpunth M, Demierre MF, Goldberg LJ. J Cutan Pathol. 2009 Dec; 36(12):1303-7. Epub 2009 Jun 9.
Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib.
J Am Acad Dermatol. 2006
Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib.
Graves JE, Jones BF, Lind AC, Heffernan MP. J Am Acad Dermatol. 2006 Aug; 55(2):349-53.
[Adverse cutaneous reactions to erlotinib].
Actas Dermosifiliogr. 2008
[Adverse cutaneous reactions to erlotinib].
Pitarch G, Garde J, Torrijos A, Juárez A, Febrer MI, Camps C. Actas Dermosifiliogr. 2008 Jan-Feb; 99(1):54-60.
Review Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Drug Resist Updat. 2011
Review Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M, Stordal B. Drug Resist Updat. 2011 Jun; 14(3):177-90. Epub 2011 Mar 24.
Review Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
J Thorac Oncol. 2008
Review Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Riely GJ. J Thorac Oncol. 2008 Jun; 3(6 Suppl 2):S146-9.